COVID-19 was discovered in December 2019, and new therapeutics and novel approaches are still needed to treat it. Worldwide, researchers engaged in developing therapeutics are exploring COVID-19 prevention strategies, and therapeutic options including convalescent plasma, monoclonal antibodies, vaccines, peptides, interferons, small molecule drugs, and reutilizing proven drugs. While vaccination provides strong immune protection against COVID-19, however, developing effective vaccines is a long and challenging process. In addition, as new variants of COVID-19 emerge, vaccines too need to be modified accordingly and administered periodically to develop re-immune protection against new variants. Alternatively, antibody-based therapy can provide immediate effect for COVID-19 patients. Neutralizing antibodies (NAbs) target viral surface proteins by blocking the attachment of virus to the host cell. Several structural studies on SARS-CoV-2-antibody interaction clearly suggest neutralizing antibodies primarily target S(spike) protein, which mediates entry into the cells. Several scientific advancements have been achieved toward COVID-19 cure in recent times, and different strategies are under testing. One of the research lines drawing more attention is the development of approaches to block the virus-cell interaction. In fact, the combination of different approaches will be necessary to achieve the final aim of COVID-19 elimination.
We seek Original Research Articles, Reviews, Mini-Reviews, Perspectives, and Brief Research Reports that discuss the latest developments in immune-antibody technologies and protection strategies aimed at the recognition and clearance of COVID-19. More specifically, topics of interest include, but are not limited to:
- Monoclonal, either broadly neutralizing or non-neutralizing, and bispecific antibodies to
target COVID-19 spike protein-cell interaction.
- Hybridoma technology for developing effective neutralizing COVID-19 antibodies either for
treatment or detection.
- Clinical studies using neutralizing antibodies therapies as COVID-19 treatment
- Convalescent plasma technology.
- Genetic engineered COVID-19 antibodies for treatment or detection.
- Animal models to test immune and antibody-based approaches to eradicate COVID-19
infection in vivo.
- Small molecule COVID-19 inhibitors.
- Therapeutic vaccines.
COVID-19 was discovered in December 2019, and new therapeutics and novel approaches are still needed to treat it. Worldwide, researchers engaged in developing therapeutics are exploring COVID-19 prevention strategies, and therapeutic options including convalescent plasma, monoclonal antibodies, vaccines, peptides, interferons, small molecule drugs, and reutilizing proven drugs. While vaccination provides strong immune protection against COVID-19, however, developing effective vaccines is a long and challenging process. In addition, as new variants of COVID-19 emerge, vaccines too need to be modified accordingly and administered periodically to develop re-immune protection against new variants. Alternatively, antibody-based therapy can provide immediate effect for COVID-19 patients. Neutralizing antibodies (NAbs) target viral surface proteins by blocking the attachment of virus to the host cell. Several structural studies on SARS-CoV-2-antibody interaction clearly suggest neutralizing antibodies primarily target S(spike) protein, which mediates entry into the cells. Several scientific advancements have been achieved toward COVID-19 cure in recent times, and different strategies are under testing. One of the research lines drawing more attention is the development of approaches to block the virus-cell interaction. In fact, the combination of different approaches will be necessary to achieve the final aim of COVID-19 elimination.
We seek Original Research Articles, Reviews, Mini-Reviews, Perspectives, and Brief Research Reports that discuss the latest developments in immune-antibody technologies and protection strategies aimed at the recognition and clearance of COVID-19. More specifically, topics of interest include, but are not limited to:
- Monoclonal, either broadly neutralizing or non-neutralizing, and bispecific antibodies to
target COVID-19 spike protein-cell interaction.
- Hybridoma technology for developing effective neutralizing COVID-19 antibodies either for
treatment or detection.
- Clinical studies using neutralizing antibodies therapies as COVID-19 treatment
- Convalescent plasma technology.
- Genetic engineered COVID-19 antibodies for treatment or detection.
- Animal models to test immune and antibody-based approaches to eradicate COVID-19
infection in vivo.
- Small molecule COVID-19 inhibitors.
- Therapeutic vaccines.